Abstract |
Forty-seven patients with advanced Hodgkin's disease were entered in a prospective, randomized trial comparing MOPP ( mechlorethamine, vincristine, procarbazine, and prednisone) with a regimen containing lomustine ( CCNU), vinblastine, and prednisone ( CCNU-VP). Both groups were comparable for the variables of age, stage, substage (symptoms), histology, prior radiation, and sites of involvement. Seventy-two percent of CCNU-VP-treated patients achieved a pathologically documented complete remission (CR) compared to 41% of the MOPP-treated group. Two additional patients treated with MOPP had remission documented only clinically but have been long-term, disease-free survivors. There was a greater frequency of CR in the patients who had received previous irradiation when compared to patients with no prior irradiation. After a median follow-up of greater than 89 months, there is no statistical difference between the two treatment groups in survival (45% for MOPP and 60% for CCNU-VP). Further, no statistical difference in survival for the two treatment groups was noted when compared by histology, stage, or symptoms. The CCNU-VP combination was better tolerated with significantly less nausea and emesis. The alternative drug regimen of CCNU-VP appears to be as effective as MOPP in producing CR and long-term survival in patients with advanced Hodgkin's disease.
|
Authors | H A Liebman, G J Hum, W W Sheehan, V M Ryden, J R Bateman |
Journal | Cancer treatment reports
(Cancer Treat Rep)
Vol. 67
Issue 5
Pg. 413-9
(May 1983)
ISSN: 0361-5960 [Print] United States |
PMID | 6342771
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- Procarbazine
- Mechlorethamine
- Vincristine
- Vinblastine
- Lomustine
- Prednisone
|
Topics |
- Adult
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials as Topic
- Drug Therapy, Combination
- Female
- Hodgkin Disease
(drug therapy)
- Humans
- Lomustine
(administration & dosage, adverse effects)
- Male
- Mechlorethamine
(administration & dosage, adverse effects)
- Nitrosourea Compounds
(administration & dosage)
- Prednisone
(administration & dosage, adverse effects)
- Procarbazine
(administration & dosage, adverse effects)
- Prognosis
- Prospective Studies
- Random Allocation
- Vinblastine
(administration & dosage, adverse effects)
- Vincristine
(administration & dosage, adverse effects)
|